Compare FCCO & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCCO | SLN |
|---|---|---|
| Founded | 1994 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 236.2M |
| IPO Year | 2012 | N/A |
| Metric | FCCO | SLN |
|---|---|---|
| Price | $30.07 | $6.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 61.4K | ★ 174.2K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 36.46 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $922,000.00 | N/A |
| Revenue This Year | $30.67 | N/A |
| Revenue Next Year | $5.87 | N/A |
| P/E Ratio | $51.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.80 | $4.19 |
| 52 Week High | $31.51 | $8.40 |
| Indicator | FCCO | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 52.19 |
| Support Level | $29.16 | $5.76 |
| Resistance Level | $31.21 | $7.53 |
| Average True Range (ATR) | 0.67 | 0.58 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 56.64 | 66.18 |
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.